Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Stemler, J; Mellinghoff, SC; Khodamoradi, Y; Sprute, R; Classen, AY; Zapke, SE; Hoenigl, M; Krause, R; Schmidt-Hieber, M; Heinz, WJ; Klein, M; Koehler, P; Liss, B; Koldehoff, M; Buhl, C; Penack, O; Maschmeyer, G; Schalk, E; Lass-Flörl, C; Karthaus, M; Ruhnke, M; Cornely, OA; Teschner, D.
Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
J Antimicrob Chemother. 2023; 78(8):1813-1826
Doi: 10.1093/jac/dkad143
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Hönigl Martin
- Krause Robert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Patients with haematological malignancies (HM) are at high risk of developing invasive fungal disease (IFD) with high morbidity and attributable mortality. We reviewed data published until September 2021 to update the 2017 antifungal prophylaxis recommendations of the German Society of Haematology and Medical Oncology (DGHO). The strong recommendation to administer antifungal prophylaxis in patients with HM with long-lasting neutropenia, i.e. <500 cells/μL for >7 days remains unchanged. Posaconazole remains the drug of choice for mould-active prophylaxis in these patients. Novel treatment options in HM, such as CAR-T-cell treatment or novel targeted therapies for acute myeloid leukaemia (AML) were considered, however, data are insufficient to give general recommendations for routine antifungal prophylaxis in these patients. Major changes regarding specific recommendations compared to the 2017 edition are the now moderate instead of mild support for the recommendations of isavuconazole and voriconazole. Furthermore, published evidence on micafungin allows recommending it at moderate strength for its use in HM. For the first time we included recommendations for non-pharmaceutical measures regarding IFD, comprising the use of high-efficiency particulate air (HEPA) filters, smoking, measures during construction work and neutropenic diets. We reviewed the impact of antifungal prophylaxis with triazoles on drug-drug interactions with novel targeted therapies that are metabolized via cytochrome p450 where triazoles inhibit CYP3A4/5. The working group recommends reducing the dose of venetoclax when used concomitantly with strong CYP3A4 inhibiting antifungals. Furthermore, we reviewed data on the prophylactic use of novel antifungal agents. Currently there is no evidence to support their use in a prophylactic setting in clinical practice.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Antifungal Agents - therapeutic use
- Cytochrome P-450 CYP3A - administration & dosage
- Invasive Fungal Infections - drug therapy, prevention & control, microbiology
- Communicable Diseases - drug therapy
- Hematologic Neoplasms - complications, drug therapy
- Hematology - administration & dosage
- Medical Oncology - administration & dosage
- Triazoles - therapeutic use